Drug Profile
Research programme: anti-cancer immunotherapies - Nouscom
Alternative Names: Neoantigen vaccines; NOUS THV 001; Oncolytic antigenless vaccinesLatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Nouscom
- Class Cancer vaccines; Oncolytic viruses
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Cancer in Switzerland
- 13 Nov 2017 Preclinical data for Cancer released by NousCom
- 09 Nov 2017 Preclinical trials in Cancer in Switzerland (unspecified route), before November 2017 (Nouscom pipeline, November 2017)